论文部分内容阅读
术前对可手术乳腺癌进行新辅助治疗(又称术前治疗)的主要临床目的是降低肿瘤分期、减少根治术的比率。辅助治疗的临床试验往往需斥巨资,并且耗时数年才能完成,而小规模新辅助治疗的临床试验将体内原发肿瘤作为观察指标,短期内通过肿瘤对治疗敏感性的分析(包括临床、病理、生物学特点)即可准确地预测长期疗效。例如:IMPACT 临床试验(术前直接比较阿那曲唑和他莫昔芬),入组300例
The main clinical goal of neoadjuvant surgery (also referred to as preoperative treatment) of preoperative breast cancer surgery is to reduce the staging of tumors and to reduce the rate of radical surgery. Clinical trials of adjuvant therapy often require large sums of money and can take years to complete, whereas small-scale neoadjuvant clinical trials target primary tumors in the body as an indicator of short-term tumor sensitivity to therapy (including clinical , Pathology, biological characteristics) can accurately predict the long-term efficacy. For example: IMPACT clinical trials (preoperative direct comparison of anastrozole and tamoxifen), enrolled 300 patients